3//SEC Filing
Pivotal bioVenture Partners Fund I, L.P. 3
Accession 0001012975-25-000705
CIK 0002044725other
Filed
Nov 4, 7:00 PM ET
Accepted
Nov 5, 8:11 PM ET
Size
21.7 KB
Accession
0001012975-25-000705
Insider Transaction Report
Form 3
Evommune, Inc.EVMN
Pivotal bioVenture Partners Fund I G.P., L.P.
Director10% Owner
Holdings
- (indirect: See footnotes)
Series Seed Preferred Stock
→ Common Stock (419,441 underlying) - (indirect: See footnotes)
Series B Preferred Stock
→ Common Stock (267,367 underlying) - (indirect: See footnotes)
Series C Preferred Stock
→ Common Stock (36,812 underlying) - (indirect: See footnotes)
Series C Preferred Stock
→ Common Stock (36,812 underlying) - (indirect: See footnotes)
Series Seed Preferred Stock
→ Common Stock (838,886 underlying) - (indirect: See footnotes)
Series A Preferred Stock
→ Common Stock (324,578 underlying) - (indirect: See footnotes)
Series B Preferred Stock
→ Common Stock (240,756 underlying) - (indirect: See footnotes)
Series A Preferred Stock
→ Common Stock (908,821 underlying) - (indirect: See footnotes)
Series C Preferred Stock
→ Common Stock (294,502 underlying)
Pivotal bioVenture Partners Fund I U.G.P. Ltd
Director10% Owner
Holdings
- (indirect: See footnotes)
Series B Preferred Stock
→ Common Stock (267,367 underlying) - (indirect: See footnotes)
Series C Preferred Stock
→ Common Stock (36,812 underlying) - (indirect: See footnotes)
Series C Preferred Stock
→ Common Stock (294,502 underlying) - (indirect: See footnotes)
Series Seed Preferred Stock
→ Common Stock (419,441 underlying) - (indirect: See footnotes)
Series A Preferred Stock
→ Common Stock (324,578 underlying) - (indirect: See footnotes)
Series B Preferred Stock
→ Common Stock (240,756 underlying) - (indirect: See footnotes)
Series Seed Preferred Stock
→ Common Stock (838,886 underlying) - (indirect: See footnotes)
Series A Preferred Stock
→ Common Stock (908,821 underlying) - (indirect: See footnotes)
Series C Preferred Stock
→ Common Stock (36,812 underlying)
Pivotal bioVenture Partners Fund I, L.P.
Director10% Owner
Holdings
- (indirect: See footnotes)
Series A Preferred Stock
→ Common Stock (324,578 underlying) - (indirect: See footnotes)
Series A Preferred Stock
→ Common Stock (908,821 underlying) - (indirect: See footnotes)
Series C Preferred Stock
→ Common Stock (294,502 underlying) - (indirect: See footnotes)
Series Seed Preferred Stock
→ Common Stock (419,441 underlying) - (indirect: See footnotes)
Series B Preferred Stock
→ Common Stock (240,756 underlying) - (indirect: See footnotes)
Series C Preferred Stock
→ Common Stock (36,812 underlying) - (indirect: See footnotes)
Series C Preferred Stock
→ Common Stock (36,812 underlying) - (indirect: See footnotes)
Series Seed Preferred Stock
→ Common Stock (838,886 underlying) - (indirect: See footnotes)
Series B Preferred Stock
→ Common Stock (267,367 underlying)
Footnotes (10)
- [F1]The Series Seed Preferred Stock is convertible into Common Stock on a 1-for-8.518 basis and has no expiration date. Upon the closing of the Issuer's initial public offering (the "IPO"), all shares of Series Seed Preferred Stock will be converted into shares of Common Stock.
- [F10]The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by NFLS Delta. Mr. Kam Chung Leung, Mr. Vincent Sai Sing Cheung, Mr. Stephen Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao, Ms. Anna Xintong Sun, Mr. Peter Bisgaard, and Dr. Robert Hopfner are the members of the Executive Committee of NFGHL. Such persons and entities disclaim beneficial ownership of these securities except to the extent of their or its proportionate pecuniary interest therein.
- [F2]The Series A Preferred Stock is convertible into Common Stock on a 1-for-7.9557 basis and has no expiration date. Upon the closing of the Issuer's IPO, all shares of Series A Preferred Stock will be converted into shares of Common Stock of the Issuer.
- [F3]The Series B Preferred Stock is convertible into Common Stock on a 1-for-7.8721 basis and has no expiration date. Upon the closing of the Issuer's IPO, all shares of Series B Preferred Stock will be converted into shares of Common Stock of the Issuer.
- [F4]The Series C Preferred Stock is convertible into Common Stock on a 1-for-8.518 basis and has no expiration date. Upon the closing of the Issuer's IPO, all shares of Series C Preferred Stock will be converted into shares of Common Stock of the Issuer.
- [F5]Held directly by NFLS Delta III Limited ("NFLS Delta"). NFLS Delta is a wholly owned, indirect subsidiary of Nan Fung Group Holdings Limited ("NFGHL").
- [F6]Held directly by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal I").
- [F7]Held directly by Pivotal bioVenture Partners Fund II, L.P. ("Pivotal II").
- [F8]The general partner of Pivotal I is Pivotal bioVenture Partners Fund I G.P., L.P. ("Pivotal GP I") and the general partner of Pivotal II is Pivotal bioVenture Partners Fund II G.P. Ltd ("Pivotal GP II"). The general partner of Pivotal GP I is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the "Ultimate General Partner"). The Ultimate General Partner and Pivotal GP II are each wholly owned by Pivotal Partners Ltd ("Pivotal Partners"). Pivotal Partners is wholly owned by Pivotal Life Sciences Holdings Limited ("Pivotal Life Sciences"). Pivotal Life Sciences is wholly owned by Nan Fung Life Sciences Holdings Limited ("Nan Fung Life Sciences"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings Limited ("NFIHL"), which is wholly owned by NFGHL. Dr. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer.
- [F9]The members of the Investment Committees of Pivotal GP I and Pivotal GP II make investment decisions with respect to the securities of the Issuer held by Pivotal I and Pivotal II. Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard, and Dr. Robert Hopfner are the members of the Investment Committees of Pivotal GP I and Pivotal GP II. Such persons and entities disclaim beneficial ownership of these securities except to the extent of their or its proportionate pecuniary interest therein.
Issuer
Evommune, Inc.
CIK 0002044725
Entity typeother
IncorporatedCayman Islands
Related Parties
1- filerCIK 0001695076
Filing Metadata
- Form type
- 3
- Filed
- Nov 4, 7:00 PM ET
- Accepted
- Nov 5, 8:11 PM ET
- Size
- 21.7 KB